LysaKare

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0019	Update of sections 4.2, 4.4 and 4.9 of the SmPC in order to align it with Lutathera SmPC based on post-marketing data and literature. In addition, the MAH took the opportunity to implement editorial changes to the PI and to update the list of local representatives in the Package Leaflet.	27/03/2025		SmPC and PL	SmPC new text Section 4.2 the following sentence are added: Under Antiemetics: "In case of severe nausea or vomiting during the infusion of LysaKare despite administration of a preventive antiemetic, an antiemetic of a different pharmacological class can be administered".

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				Instruction for infusion of LysaKare and lutetium (177Lu) oxodotreotide through a separate venous access in each of the patient's arms is also added. Section 4.2 under Renal Impairment and section 4.4 under Hyperkalaemia and Renal Impairment: Information about the potential increased risk of transient hyperkalaemia in these patients is added and contraindications are clarified. Section 4.4 Hepatic impairment: prothrombin ratio <70% is substituted by INR>1.5 in the relevant warning Section 4.9 Overdose Micturition is removed from recommended elimination options For more information, please refer to the Summary of Product Characteristics.
II/0018	Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the warning on 'Hyperkalaemia' as well as on 'Metabolic acidosis' and to update safety information based on final results from study CAAA001A12401 listed as a category 3 study in the RMP. This is a multicenter, open-label post authorization safety study to evaluate the effect of LysaKare infusion on serum potassium levels in GEP-NET patients eligible for Lutathera treatment. The RMP version 3.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	13/03/2025		SmPC	SmPC new text Section 4.4 Hyperkalaemia It is clarified that an increase in serum potassium occurs in most patients treated with LysaKare which are generally mild and transient. Metabolic acidosis The following sentence is added: "Metabolic acidosis was also observed with LysaKare based on laboratory parameters only, which usually resolved within 24 hours of administration, and without clinical symptoms." Section 5.1 Results from a Phase IV multicentre open-label study conducted to assess the effect of LysaKare on serum potassium concentrations and characterisation of the safety profile are added showing that "There were no serious adverse events leading to treatment interruption or

					discontinuation reported during this study. Overall, the safety profile of LysaKare remains consistent with the current safety profile as presented based on literature and clinical practice.” For more information, please refer to the Summary of Product Characteristics.
R/0016	Renewal of the marketing authorisation.	22/02/2024	25/04/2024	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of LysaKare in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Minor changes are implemented in the PI in line with the latest QRD template. Relevant statements have been added in sections 4.2 for the Elderly and Hepatic impairment and 4.6 for women of childbearing potential, contraception, and pregnancy of the SmPC. Sections of Warning and precautions and Possibleside effects of the PL have also been updated.
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	08/02/2024	25/04/2024	PL	
PSUSA/10786 /202307	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	08/02/2024	n/a		PRAC Recommendation - maintenance
N/0014	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/09/2023	16/02/2024	PL	
IAIN/0013	A.1 - Administrative change - Change in the name and/or address of the MAH	13/02/2023	16/02/2024	SmPC, Labelling and PL	
PSUSA/10786	Periodic Safety Update EU Single assessment - l-	09/02/2023	n/a		PRAC Recommendation - maintenance

/202207	lysine hydrochloride / l-arginine hydrochloride				
IB/0012	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	25/11/2022	n/a		
PSUSA/10786 /202201	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	01/09/2022	n/a		PRAC Recommendation - maintenance
N/0010	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	23/06/2022	16/02/2024	PL	
PSUSA/10786 /202107	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	10/02/2022	n/a		PRAC Recommendation - maintenance
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/10/2021	16/02/2024	PL	
PSUSA/10786 /202101	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	02/09/2021	n/a		PRAC Recommendation - maintenance
PSUSA/10786 /202007	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	11/02/2021	n/a		PRAC Recommendation - maintenance
PSUSA/10786 /202001	Periodic Safety Update EU Single assessment - l-lysine hydrochloride / l-arginine hydrochloride	03/09/2020	n/a		PRAC Recommendation - maintenance
IB/0003	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	27/03/2020	n/a		

IA/0002	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	17/01/2020	n/a		
IA/0001	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	17/12/2019	n/a		